论文部分内容阅读
美国从1948年汗始将吸入皮质类固醇曲安缩松(TAA)用于治疗成人及≤6岁的儿童慢性哮喘,它是用含氯氟烃(CFC)即二氯二氟烷(P-12)作为抛射剂,以定量式吸入器加间隔器供患者使用的。约有20％的患者吸入激素而且TAA占相当比例。但近年CFCs包括P-12被提出能破坏大气臭氧层,此后包括美国在内的许多国家已认可用更具环保作用的抛射剂,在医用气溶胶中取代CFCs。有一种抛射剂是氯氟烷烃-134a(HFA),对臭氧层影响不大,并且毒性作用时间较短。
The United States started inhalation of the corticosteroid triamcinolone (TAA) from 1948 to treat chronic asthma in adults and children ≤ 6 years of age using chlorofluorocarbons (CFCs), dichlorodifluoromethane (P-12 ) As a propellant, with a metered dose inhaler plus spacer for patient use. About 20% of patients inhaled hormones and TAA accounted for a considerable proportion. However, in recent years, CFCs including P-12 have been proposed to damage the atmospheric ozone layer. Since then, many countries including the United States have accepted the replacement of CFCs in medical aerosols with more environmentally friendly propellants. One such propellant is chlorofluoroalkane-134a (HFA), which has little effect on the ozone layer and has a short duration of toxicity.